Drug
Vortioxetine
Vortioxetine: highest development phase Post-Market, developed by Lundbeck, Takeda. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Lundbeck, Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vortioxetine NCT04220996 | Post-Market | MDD |
| Vortioxetine NCT00730691 | Phase 3 | Generalized Anxiety Disorder |
| Vortioxetine NCT00731120 | Phase 3 | Generalized Anxiety Disorder |
| Vortioxetine (IV) NCT02919501 | Phase 2 | Depressive Disorder, Major |
Latest
No recent events.
Follow Vortioxetine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.